On September 28, the opening ceremony of Leadingpharm (Chongqing) Medical Technology Co., Ltd. was held in Yongchuan. 15 high-end preparation projects have been officially launched.

▲ The Opening Ceremony of Leadingpharm (Chongqing) Medical Technology
 

Zhikui Zhang, Secretary of the CPC Yongchuan District Committee; Xiaoyong Chang, Deputy Secretary of the CPC Yongchuan District Committee and Head of the District Government; Longhai Zhou, First-level Inspector and former Director of Chongqing Drug Administration; Yanming Li, former Director of the People's Congress of Shizhu County and Head of the Industrial Leading Group of Shizhu Coptis Chinensis Industry; Wallace Tao, Chairman of Leadingpharm； Julie Gao, President of Leadingpharm; Jinge Chen, General Manager of Zhengzhou Hi-tech Industry Investment Group and Director of Taloph Group; Luo Jianchao, General Manager of Taloph Group, and other leaders and more than 20 enterprise representatives attended the event, which was presided over by Wen Deng, member of the Standing Committee of Yongchuan District Committee and Executive Deputy Head of the District Government.
 

▲The project was unveiled by Zhikui Zhang (left), Secretary of Yongchuan District Party Committee, and Wallace Tao (right), Chairman of Leadingpharm
 

▲ Projects were Jointly Started
 

Leadingpharm (Chongqing) Biomedical Integrated R&D Service Base Project is divided into two phases. Leadingpharm (Chongqing) Medical Technology and Benlifang MAH have been completed and officially put into operation as the first phase project. The laboratory covers an area of more than 4000 square meters and is equipped with high-end solid preparation research and development ，pilot scale-up production and related testing equipment. At present, 15 high-end API and preparation projects have been launched. It is estimated that by the end of 2025, the number of declared projects will not be less than 30, and the number of MAH approvals settled in Yongchuan will not be less than 10, with a total output value of more than 500 million. The Phase II Project will start the construction of CRO company of cell and gene therapy, CDMO base, Chongqing MAH information platform and management center, which will truly make Yongchuan a medical R&D highland in  Cheng-Yu District!
 

▲Leadingpharm （Chongqing）R&D Laboratory
 

At the same time, as a leading pharmaceutical R&D enterprise in China, Leadingpharm has a mature and perfect pharmaceutical R&D management system, rich project experience and a team of thousands of senior experts at home and abroad, and has established the CXO ecosystem covering the whole industrial chain of pharmaceutical R&D. The implementation of Leadingpharm (Chongqing) Medical Technology will introduce the high-end pharmaceutical research and development, clinical research and other links with high demand for technology, team and management into Yongchuan, improve the whole industrial chain of Chongqing pharmaceutical R & D, which will certainly help Yongchuan District to build into a biopharmaceutical industry cluster with national influence, and inject new vitality into the development of Chongqing and even China's pharmaceutical industry!

-END-